Tryptamine Therapeutics (ASX:TYP) completed the dosing component of its phase 1b trial, administering the intravenous-infused psilocin TRP-8803 in three obese individuals, according to a Friday filing with the Australian bourse.
Psilocin is used in psychedelic-assisted psychotherapy and has potential neuroplastic benefits, which may help in providing structural and functional changes in the brain.
The trial aims to compare the pharmacokinetic profile of psilocybin in obese individuals with non-obese individuals, the filing said.
Results will be used to advance the program into a phase 2 trial investigating the use of TRP-8803 in weight-related indications such as binge-eating disorder, the filing added.
Company shares rose nearly 5% in recent Friday trade.
Price (AUD): $0.05, Change: $+0.002, Percent Change: +4.65%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.